BARDA partners with Hoxworth Blood Center to develop and validate an improved method to evaluate next-generation blood products
To further prioritize the advanced development of next-generation blood products for use, BARDA is partnering with Hoxworth Blood Center, University of Cincinnati, to develop an improved alternative method to assess blood products in regulatory studies.
Hoxworth Blood Center will conduct pre-clinical and clinical trials to compare Biotinylation to Chromium-51 to evaluate the safety and efficacy of using a non-radioactive alternative labeling method to assess blood products. If biotin is found to be a more effective labeling alternative, it could result in many improvements of safety and availability of blood products in radiological or nuclear mass casualty incidents (MCI).
Biotin (vitamin B7) is an essential nutrient that helps the human body metabolize fatty acids, glucose, and amino acids and is naturally present in food and is available as a dietary supplement. Since it is more widely found, it could help improve the amount of blood products available for patients that need it. Additionally, the U.S. has only one producer of Chromium-51 which could result in less product availability and potential shortages.
Cr-51 is a synthetic radioactive isotope of chromium used to label RBCs to facilitate measurement of circulating RBC mass, volume, and survival time. The use of Cr-51 exposes research subjects and laboratory technicians to radiation and limits the number of laboratories permitted to perform testing due to regulation requirements, such as needing to obtain a special license and may be subject to state or U.S. Nuclear Regulatory Commission guidelines for possessing/using radioactive materials. Additionally, more laboratories could evaluate blood products and novel blood products candidates, including those for use in transfusion in the context of public health emergencies and routine medical treatment and would be a safer alternative to using Cr-51 because it is not radioactive.
Under the agreement, BARDA will provide funding and expertise for a clinical trial to validate biotin, a naturally occurring vitamin, as a safe and effective option to replace chromium 51 (Cr-51) as the U.S. Food and Drug Administration’s (FDA’s) current “gold standard” labeling method for measurement of circulating red blood cells (RBCs). BARDA invests in next generation blood product candidates that address hematopoietic injuries and build blood system capacity, including those that have long shelf-lives, are stable at higher temperatures, and can be administered in the field or enroute to a hospital. These investments rely on enabling technologies, such as safer labeling methods that enable evaluation of circulating RBCs, to support regulatory approval.
This award contributes to objectives set in BARDA’s 2022-2026 Strategic Plan, which emphasizes the importance of supporting the development of enabling technologies that can facilitate the regulatory process.
This award is one component of the BARDA’s CBRN Division medical countermeasure portfolio, visit the CBRN Portfolio to learn more.
About Hoxworth:
Hoxworth Blood Center, University of Cincinnati, was founded in 1938 and serves more than 30 hospitals in 18 counties in Southwestern Ohio, Northern Kentucky, and Southeastern Indiana. Annually, Hoxworth collects more than 100,000 units of blood from local donors to help save the lives of patients in area hospitals. Hoxworth Blood Center: Saving Lives Close to Home.
Related Stories
SELF: 6 things you should know about exercise and the COVID-19 vaccines
May 4, 2021
Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases, was one of the sources cited in an article published by SELF on six things to know about exercise and COVID-19 vaccines.
Fox19: World Voice Day with UC Health
April 15, 2021
Rebecca Howell, MD, of the Department of Otolaryngology-Head and Neck Surgery in the UC College of Medicine, was interviewed by WXIX-TV, Fox19 about World Voice Day coming up on Friday, April 16.
Cincinnati.com: It's spring. You're vaccinated. We asked docs what they feel is safe, what they'd avoid
April 12, 2021
Jennifer Forrester, MD, of the UC College of Medicine Division of Infectious Diseases was one of the expert sources cited in an article on Cincinnati.com on how safe or unsafe doctors feel certain activities are as we get into spring and more and more people are vaccinated against COVID-19.
The Body: How one Black woman wrestles with vaccine hesitancy
April 20, 2021
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was one of the sources cited in an article published in The Body about the author's concern about getting the COVID-19 vaccine. Fichtenbaum stressed the safety and efficacy of the vaccines and said they would not interere with treatments for cancer and HIV/AIDS.
Medscape: New study confirms kidney dialysis worsens pregnancy outcomes
April 30, 2021
Silvi Shah, MD, of the Division of Nephrology, Kidney CARE Program, at the UC College of Medicine, was cited as a source in a Medscape story on new research showing that kidney dialysis worsens outcome for pregnant women.
WCPO-TV: Experts: Reopening states still far from herd immunity
June 8, 2021
Masks are coming off in Ohio, Kentucky and Indiana, thanks to widespread availability of the COVID-19 vaccine and politicians’ increasing willingness to let unvaccinated people roll the dice on their own health. WCPO-TV interviewed Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases who said any amount of vaccination is helpful in preventing the novel coronavirus from spreading, but unvaccinated people are still in danger as social gatherings and indoor events resume.
Cincinnati.com: COVID-19: When will Ohio gain protective herd immunity from vaccines? Doctors can't be sure
April 6, 2021
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was one of three experts Cincinnati.com turned to on a story about when Ohio will gain herd immunity against COVID-19.
Faculty Awards 2021: Kenneth Sherman
April 8, 2021
Kenneth E. Sherman, MD, PhD, is Gould Professor of Medicine and Director of the UC Division of Digestive Diseases in the Department of Internal Medicine. He is this year recipient of the University of Cincinnati Distinguished Research Professor Award.
Good Housekeeping: When will kids get COVID-19 vaccines? Experts share a timeline to keep in mind
April 9, 2021
Carl Fichtenbaum, MD, of the Division of Infectious Diseases in the UC College of Medicine was featured in an article in Good Housekeeping on when we can expect to see COVID-19 vaccines ready to be given to children.
Local 12: What researchers say we should know about heart inflammation and COVID-19 vaccine
May 25, 2021
Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases was interviewed by two local TV stations for a story they did on myocarditis and COVID-19 vaccines. An advisory committee to the CDC is looking into reports that some teenagers and young adults who have received the COVID-19 vaccine have experienced heart inflammation. They’re reviewing these cases to see if there’s a possible connection.